Equities Analysts Issue Forecasts for Elutia FY2026 Earnings

Elutia Inc. (NASDAQ:ELUT - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Elutia in a report released on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings of ($0.17) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $8.00 price objective on the stock. The consensus estimate for Elutia's current full-year earnings is ($1.74) per share.

Separately, Lake Street Capital reduced their price objective on shares of Elutia from $10.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, May 9th.

Elutia Stock Performance

Shares of NASDAQ:ELUT traded down $0.11 during midday trading on Tuesday, reaching $1.78. The company had a trading volume of 10,970 shares, compared to its average volume of 50,661. The company has a fifty day simple moving average of $2.00 and a two-hundred day simple moving average of $2.86. The firm has a market cap of $73.19 million, a price-to-earnings ratio of -0.68 and a beta of 0.86. Elutia has a 1-year low of $1.61 and a 1-year high of $5.24.

Elutia (NASDAQ:ELUT - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.01). The company had revenue of $6.03 million during the quarter, compared to analyst estimates of $6.65 million.

Institutional Trading of Elutia

Several large investors have recently added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp bought a new position in shares of Elutia during the 1st quarter valued at $28,000. Jane Street Group LLC acquired a new position in Elutia during the first quarter worth $48,000. Arcus Capital Partners LLC bought a new position in Elutia during the first quarter valued at about $51,000. Northern Trust Corp raised its holdings in Elutia by 30.0% during the fourth quarter. Northern Trust Corp now owns 17,957 shares of the company's stock valued at $67,000 after buying an additional 4,148 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Elutia in the fourth quarter worth about $84,000. 74.03% of the stock is owned by institutional investors.

About Elutia

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.